Top

Published in:

01-12-2014 | Review Article

Association of osteopontin with osteoarthritis

Authors: Chao Cheng, Shuguang Gao, Guanghua Lei

Published in: Rheumatology International | Issue 12/2014

Abstract

The joint disease osteoarthritis (OA) is the most common form of arthritis, which mainly affects the older people. OA is becoming one of the major non-fatal health burdens of the world. The etiology of OA is mostly unclear, and it cannot be cured totally. Osteopontin (OPN) is a multifunctional phosphoprotein, of which overexpression and high level of presence in synovial fluid and articular cartilage were found to be associated with OA progression. Usually, in OA progression, OPN plays important role as an intrinsic regulator. Recent studies have taken attempt to use this protein as a diagnostic marker of OA and use OPN as a target for the drug development against OA. This review summarizes the role of OPN in OA, with focusing on the mechanism of action, and also discussing the diagnostic and therapeutic aspects of OA related to OPN.

Laslett LL, Quinn SJ, Winzenberg TM, Sanderson K, Cicuttini F, Jones G (2012) A prospective study of the impact of musculoskeletal pain and radiographic osteoarthritis on health related quality of life in community dwelling older people. BMC Musculoskelet Disord 13:168PubMedCentralPubMedCrossRef

Garriga XM (2014) Definition, etiology, classification and presentation forms. Aten Primaria 46(Suppl 1):3–10CrossRef

Jones G (2013) Osteoarthritis: Where are we for pain and therapy in 2013? Aust Fam Physician 42(11):766–769PubMed

Neogi T (2013) The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage 21(9):1145–1153PubMedCentralPubMedCrossRef

Martín AP (2014) Symptoms, localizations: knee, hip, hands, spine, other localizations. Aten Primaria 46(Suppl 1):11–17CrossRef

Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81(9):646–656PubMedCentralPubMed

Murray CJ, Lopez AD (1996) Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 274(5288):740–743PubMedCrossRef

Brandt KD, Dieppe P, Radin E (2009) Etiopathogenesis of osteoarthritis. Med Clin North Am 93(1):1–24, xv

Leung GJ, Rainsford KD, Kean WF (2014) Osteoarthritis of the hand I: aetiology and pathogenesis, risk factors, investigation and diagnosis. J Pharm Pharmacol 66(3):339–346PubMedCrossRef

10.

de Rezende MU, de Campos GC, Pailo AF (2013) Current concepts in osteoarthritis. Acta Ortop Bras 21(2):120–122PubMedCentralPubMedCrossRef

11.

Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18(4):476–499PubMedCrossRef

12.

Vargas Negrín F, Medina Abellán MD, Hermosa Hernán JC, de Felipe Medina R (2014) Treatment of patients with osteoarthritis. Aten Primaria 46(Suppl 1):39–61PubMedCrossRef

13.

Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, Bridgett L, Williams S, Guillemin F, Hill CL, Laslett LL, Jones G, Cicuttini F, Osborne R, Vos T, Buchbinder R, Woolf A, March L (2014) The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204763

14.

Standal T, Borset M, Sundan A (2004) Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26(3):179–184PubMed

15.

Hasegawa M, Nakoshi Y, Iino T, Sudo A, Segawa T, Maeda M, Yoshida T, Uchida A (2009) Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis. J Rheumatol 36(2):240–245PubMedCrossRef

16.

Yamaga M, Tsuji K, Miyatake K, Yamada J, Abula K, Ju YJ, Sekiya I, Muneta T (2012) Osteopontin level in synovial fluid is associated with the severity of joint pain and cartilage degradation after anterior cruciate ligament rupture. PLoS One 7(11):e49014PubMedCentralPubMedCrossRef

17.

O’Regan A, Berman JS (2000) Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 81(6):373–390PubMedCentralPubMedCrossRef

18.

Gao SG, Li KH, Zeng KB, Tu M, Xu M, Lei GH (2010) Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients. Osteoarthritis Cartilage 18(1):82–87PubMedCrossRef

19.

Elsebaie H, Elchamy HA, Kaddah EA, Abdelfatta RG (2012) Osteopontin in patients with primary knee osteoarthritis: relation to disease severity. Life Sci J 9(4):3902–3909

20.

Ohshima S, Kobayashi H, Yamaguchi N, Nishioka K, Umeshita-Sasai M, Mima T, Nomura S, Kon S, Inobe M, Uede T, Saeki Y (2002) Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum 46(4):1094–1101PubMedCrossRef

21.

Jiang Y, Yao M, Liu Q, Zhou C (2013) OPN gene polymorphisms influence the risk of knee OA and OPN levels in synovial fluid in a Chinese population. Arthritis Res Ther 15(1):R3PubMedCentralPubMedCrossRef

22.

Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK (2008) Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 47(12):1775–1779CrossRef

23.

Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19(5–6):333–345PubMedCrossRef

24.

Matsui Y, Iwasaki N, Kon S, Takahashi D, Morimoto J, Matsui Y, Denhardt DT, Rittling S, Minami A, Uede T (2009) Accelerated development of aging-associated and instability-induced osteoarthritis in osteopontin-deficient mice. Arthritis Rheum 60(8):2362–2371PubMedCrossRef

25.

Honsawek S, Tanavalee A, Sakdinakiattikoon M, Chayanupatkul M, Yuktanandana P (2009) Correlation of plasma and synovial fluid osteopontin with disease severity in knee osteoarthritis. Clin Biochem 42(9):808–812PubMedCrossRef

26.

Mohammed FI, El-Azeem MIA, KamalElDin AM (2012) Plasma and synovial fluid osteopontin levels in patients with knee osteoarthritis: relation to radiological grade. Egypt Rheumatol 34(3):131–136CrossRef

27.

Qin LF, Wang WC, Fang H, Mao XZ, Huang GL, Chen Y, Zhou HD, Shen Y, Qin LH, Peng D (2013) Expression of NF-κB and osteopontin of synovial fluid of patients with knee osteoarthritis. Asian Pac J Trop Med 6(5):379–382PubMedCrossRef

28.

Xu M, Zhang L, Zhao L, Gao S, Han R, Su D, Lei G (2013) Phosphorylation of osteopontin in osteoarthritis degenerative cartilage and its effect on matrix metalloprotease 13. Rheumatol Int 33(5):1313–1319PubMedCrossRef

29.

Pullig O, Weseloh G, Gauer S, Swoboda B (2000) Osteopontin is expressed by adult human osteoarthritic chondrocytes: protein and mRNA analysis of normal and osteoarthritic cartilage. Matrix Biol 19(3):245–255PubMedCrossRef

30.

Martínez-Calleja A, Velasquillo C, Vega-López M, Arellano-Jiménez MJ, Tsutsumi-Fujiyoshi VK, Mondragón-Flores R, Kouri-Flores JB (2014) Osteopontin expression and localization of Ca++ deposits in early stages of osteoarthritis in a rat model. Histol Histopathol [Epub ahead of print]

31.

Zhang FJ, Gao SG, Cheng L, Tian J, Xu WS, Luo W, Song Y, Yang Y, Lei GH (2013) The effect of hyaluronic acid on osteopontin and CD44 mRNA of fibroblast-like synoviocytes in patients with osteoarthritis of the knee. Rheumatol Int 33(1):79–83PubMedCrossRef

32.

Dong X, Zheng Y, Liu HY (2013) The clinical significance of serum and joint fluid osteopontin, and thrombin-cleaved osteopontin levels in osteoarthritis. Zhonghua Nei Ke Za Zhi 52(12):1023–1027PubMed

33.

Buckwalter JA, Mankin HJ (1998) Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instr Course Lect 47:487–504PubMed

34.

Monfort J, Garcia-Giralt N, López-Armada MJ, Monllau JC, Bonilla A, Benito P, Blanco FJ (2006) Decreased metalloproteinase production as a response to mechanical pressure in human cartilage: a mechanism for homeostatic regulation. Arthritis Res Ther 8(5):R149PubMedCentralPubMedCrossRef

35.

Couchourel D, Aubry I, Delalandre A, Lavigne M, Martel-Pelletier J, Pelletier JP, Lajeunesse D (2009) Altered mineralization of human osteoarthritic osteoblasts is attributable to abnormal type I collagen production. Arthritis Rheum 60(5):1438–1450PubMedCrossRef

36.

Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD (2002) Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46(10):2613–2624PubMedCrossRef

37.

Singh A, Goel SC, Gupta KK, Kumar M, Arun GR, Patil H, Kumaraswamy V, Jha S (2014) The role of stem cells in osteoarthritis: an experimental study in rabbits. Bone Joint Res 3(2):32–37PubMedCentralPubMedCrossRef

38.

Goldring SR, Goldring MB (2006) Clinical aspects, pathology and pathophysiology of osteoarthritis. J Musculoskelet Neuronal Interact 6(4):376–378PubMed

39.

Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, Nifuji A, Uede T, Denhardt DT, Noda M (2002) Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA 99(7):4556–4561PubMedCentralPubMedCrossRef

40.

Yamamoto N, Sakai F, Kon S, Morimoto J, Kimura C, Yamazaki H, Okazaki I, Seki N, Fujii T, Uede T (2003) Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 112(2):181–188PubMedCentralPubMedCrossRef

41.

Yamamoto N, Nakashima T, Torikai M, Naruse T, Morimoto J, Kon S, Sakai F, Uede T (2007) Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody. Int Immunopharmacol 7(11):1460–1470PubMedCrossRef

42.

Fan K, Dai J, Wang H, Wei H, Cao Z, Hou S, Qian W, Wang H, Li B, Zhao J, Xu H, Yang C, Guo Y (2008) Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum 58(7):2041–2052PubMedCrossRef

Title: Association of osteopontin with osteoarthritis
Authors: Chao Cheng
Shuguang Gao
Guanghua Lei
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: Rheumatology International / Issue 12/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-014-3036-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2014

Acute physical exercise is safe in patients with primary antiphospholipid syndrome with exclusive venous thrombosis and under oral anticoagulation with warfarin

Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sjögren’s syndrome compared to systemic lupus erythematosus and rheumatoid arthritis

Soluble TNF receptors are produced at sites of inflammation and are inversely associated with self-reported symptoms (WOMAC) in knee osteoarthritis

Impact of morning stiffness on working behaviour and performance in people with rheumatoid arthritis

Divergent perceptions in health-related quality of life between family members and patients with rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis

The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials